WALTHAM, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that it will present at the following investor conferences:
Cantor Global Healthcare Conference 2025
Fireside Chat Date: Wednesday, September 3, 2025
Fireside Chat Time: 2:10 PM ET
Location: New York, NY
H.C. Wainwright 27th Annual Global Investment Conference
Fireside Chat Date: Monday, September 8, 2025
Fireside Chat Time: 12:00 PM ET
Location: New York, NY
Live webcasts of the fireside chats will be available in the investor section of the company’s website at investors.invivyd.com and will be archived for approximately 30 days following each event.
In addition to the fireside chats, the management team will host investor meetings at the conferences. Investors participating in the conferences who are interested in meeting with Invivyd management should contact their Cantor or H.C. Wainwright representative.
About Invivyd
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more.
Contacts:
Media Relations
(781) 208-1747
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations
(781) 208-1747
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.19 |
| Daily Change: | 0.04 1.86 |
| Daily Volume: | 369,608 |
| Market Cap: | US$469.560M |
October 28, 2025 October 06, 2025 September 24, 2025 September 04, 2025 August 22, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
